Related Experiment Videos
Immunoscintigraphy with 111In antimyosin Fab
A J Morguet1, D L Munz, H Kreuzer
1Department of Cardiology and Pulmonology, Georg-August University, Göttingen, West Germany.
Nuclear Medicine Communications
|November 1, 1990
Summary
111In antimyosin Fab immunoscintigraphy detects damaged heart cells, aiding in diagnosing conditions like myocardial infarction and transplant rejection. While its delayed imaging limits acute use, it offers valuable insights into subacute cardiac issues and other heart conditions.
Area of Science:
- Nuclear Medicine
- Cardiology
- Immunoscintigraphy
Background:
- Monoclonal 111In antimyosin Fab targets myocytes with membrane damage.
- Slow blood pool clearance necessitates a 24-48 hour imaging delay post-injection.
- This delay limits its use in acute myocardial infarction diagnosis.
Purpose of the Study:
- To explore the diagnostic utility of 111In antimyosin Fab immunoscintigraphy.
- To evaluate its role beyond acute myocardial infarction diagnosis.
- To assess its potential in various cardiac conditions and monitoring.
Main Methods:
- Intravenous injection of 74 MBq of 111In antimyosin Fab tracer.
- Delayed imaging 24-48 hours post-injection.
- Application in differentiating necrotic from viable myocardium and diagnosing other cardiac pathologies.
Main Results:
- Antimyosin scintigraphy can differentiate necrotic from viable myocardium in subacute infarction.
- It may supplement or replace endomyocardial biopsy for transplant rejection detection.
- Potential applications include diagnosing myocarditis, assessing cardiomyopathy prognosis, and monitoring cardiotoxicity.
Conclusions:
- 111In antimyosin Fab immunoscintigraphy provides valuable diagnostic information in specific clinical scenarios.
- Its utility extends to subacute myocardial infarction, transplant rejection, myocarditis, and monitoring cardiac health.
- Further applications include prognostic assessment and detecting cardiac tumors.